# Module 15: Infectious Diseases - Pharmacology of Selected Antibiotics Part 2

## Table of Contents
1. [Drugs for Resistant Gram-Positive Infections](#drugs-for-resistant-gram-positive-infections)
2. [Fluoroquinolones](#fluoroquinolones)
3. [Aminoglycosides](#aminoglycosides)
4. [Macrolides](#macrolides)
5. [Tetracyclines](#tetracyclines)
6. [Other Key Antibacterials](#other-key-antibacterials)

---

## Drugs for Resistant Gram-Positive Infections

### Vancomycin (Pages 2-3)

**Mechanism of Action**:
- Inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala terminus of cell wall precursor units
- Bactericidal against most Gram-positive organisms

**Spectrum of Activity**:
- **Excellent activity**: MRSA, MSSA, Streptococcus spp., Enterococcus spp.
- **No activity**: Gram-negative organisms
- **Note**: Increasing MICs in MRSA ("MIC creep") - concern for reduced efficacy

**Pharmacokinetics**:
- **Absorption**: Poor oral absorption (use oral only for C. difficile infection)
- **Distribution**: Well distributed to most tissues; poor CNS penetration
- **Elimination**: Renal excretion (adjust dose in renal impairment)
- **Half-life**: 4-6 hours in normal renal function

**Dosing**:
- **Standard**: 15-20 mg/kg IV q8-12h
- **Loading dose**: 25-30 mg/kg for serious infections
- **Target trough**: 15-20 mcg/mL for serious infections (bacteremia, pneumonia, meningitis)
- **AUC/MIC targeting**: Preferred method; target AUC 400-600

**Adverse Effects**:
- **Nephrotoxicity**: Dose-dependent; risk increases with trough >20 mcg/mL
- **Ototoxicity**: Rare; associated with high troughs
- **Red Man Syndrome**: Histamine-mediated infusion reaction (flushing, rash, hypotension)
  - Prevention: Slow infusion rate (≥1 hour per 500 mg)
  - Treatment: Antihistamines, slower infusion
- **Thrombophlebitis**: Common with peripheral IV administration

**Clinical Pearls**:
- TDM (therapeutic drug monitoring) recommended for serious infections
- Not effective for Gram-negative infections
- Consider alternatives if MIC ≥2 mcg/mL
- Synergy with aminoglycosides or rifampin for some infections

### Newer Glycopeptides (Page 3)

**Telavancin (Vibativ)**:
- Lipoglycopeptide; similar to vancomycin but longer half-life
- **Indications**: MRSA skin infections, hospital-acquired pneumonia
- **Dosing**: 10 mg/kg IV q24h
- **Adverse effects**: Similar to vancomycin; also QTc prolongation

**Dalbavancin (Dalvance)** & **Oritavancin (Orbactiv)**:
- Ultra-long half-life lipoglycopeptides
- **Single-dose therapy** for ABSSSI (acute bacterial skin/skin structure infections)
- **Dalbavancin**: 1500 mg single dose OR 1000 mg, then 500 mg one week later
- **Oritavancin**: 1200 mg single dose
- **Advantage**: Outpatient parenteral therapy without need for IV access maintenance

### Daptomycin (Cubicin) (Pages 3-4)

**Mechanism of Action**:
- Lipopeptide that inserts into bacterial cell membrane → depolarization → cell death
- Concentration-dependent bactericidal activity

**Spectrum of Activity**:
- Gram-positive organisms only (MRSA, MSSA, VRE, Strep spp.)
- **Not effective for pneumonia** (inactivated by pulmonary surfactant)

**Dosing**:
- **ABSSSI**: 4 mg/kg IV q24h
- **Bacteremia/endocarditis**: 6-8 mg/kg IV q24h (up to 10-12 mg/kg for difficult infections)
- **Adjust for CrCl <30 mL/min**: Dose q48h

**Adverse Effects**:
- **CPK elevation**: Monitor weekly; discontinue if CPK >1000 U/L with symptoms or >2000 U/L
- **Myopathy/rhabdomyolysis**: Rare but serious
- **Eosinophilic pneumonia**: Rare
- **Drug interaction**: Hold statins during therapy (increases myopathy risk)

**Clinical Pearls**:
- Rapid bactericidal activity
- No cross-resistance with vancomycin
- High penetration into biofilms
- Alternative to vancomycin for MRSA bacteremia

### Oxazolidinones (Pages 4-5)

**Linezolid (Zyvox)**:
- **MOA**: Inhibits bacterial protein synthesis (binds to 50S ribosomal subunit)
- **Spectrum**: MRSA, VRE, Strep spp., some Gram-negatives
- **Dosing**: 600 mg PO/IV q12h
- **Advantages**:
  - 100% oral bioavailability
  - Excellent tissue penetration (including CNS)
  - Active against VRE
- **Adverse effects**:
  - Myelosuppression (thrombocytopenia, anemia) - monitor CBC weekly if >2 weeks therapy
  - Peripheral/optic neuropathy (prolonged use >28 days)
  - Lactic acidosis (rare)
  - Serotonin syndrome (with SSRIs, SNRIs, MAOIs)
- **Drug interactions**: MAO inhibitor activity - avoid tyramine-rich foods

**Tedizolid (Sivextro)**:
- Second-generation oxazolidinone
- **Dosing**: 200 mg PO/IV q24h × 6 days
- **Advantages**: Lower rates of myelosuppression, once-daily dosing
- **Indication**: ABSSSI

### VRE Treatment (Page 5)

**Treatment options for Vancomycin-Resistant Enterococcus**:
1. **Linezolid**: First-line for VRE infections
2. **Daptomycin**: 8-12 mg/kg q24h (higher doses for endocarditis)
3. **Quinupristin/Dalfopristin**: VRE faecium only (not faecalis)
4. **Tigecycline**: Reserve for limited options

---

## Fluoroquinolones (Pages 6-7)

### General Characteristics

**Mechanism of Action**:
- Inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV
- Concentration-dependent bactericidal activity
- **PK/PD target**: AUC/MIC >30-40 (Gram-negatives), >100 (Streptococcus)

**Resistance Mechanisms**:
- Chromosomal mutations in DNA gyrase/topoisomerase genes
- Efflux pumps
- Plasmid-mediated resistance (qnr genes)

### Individual Agents

**Levofloxacin (Levaquin)**:
- **Spectrum**: Broad coverage of Gram-positives, Gram-negatives, atypicals
- **Indications**: CAP, UTI, ABSSSI, prostatitis
- **Dosing**: 500-750 mg PO/IV q24h
- **Oral bioavailability**: ~100%

**Moxifloxacin (Avelox)**:
- **Spectrum**: Enhanced Gram-positive and anaerobic coverage
- **Indications**: CAP, intra-abdominal infections (with metronidazole)
- **Dosing**: 400 mg PO/IV q24h
- **Note**: Poor urinary concentration - not for UTI

**Ciprofloxacin (Cipro)**:
- **Spectrum**: Excellent Gram-negative coverage (including Pseudomonas); weaker Gram-positive
- **Indications**: UTI, Pseudomonas infections, anthrax prophylaxis
- **Dosing**:
  - PO: 250-750 mg q12h
  - IV: 400 mg q12h
- **Oral bioavailability**: 70%

**Delafloxacin (Baxdela)**:
- **Spectrum**: Broad coverage including MRSA
- **Indication**: ABSSSI
- **Dosing**: 300 mg IV q12h OR 450 mg PO q12h
- **Advantage**: Active in acidic environments (abscesses)

### Adverse Effects (All Fluoroquinolones)

**Black Box Warnings**:
1. **Tendon rupture/tendinitis**: Especially Achilles tendon; risk increased with:
   - Age >60 years
   - Corticosteroid use
   - Kidney/heart/lung transplant recipients
2. **Peripheral neuropathy**: May be permanent
3. **CNS effects**: Seizures, increased intracranial pressure
4. **Aortic aneurysm/dissection**: Avoid in high-risk patients
5. **Myasthenia gravis exacerbation**: Contraindicated

**Other Adverse Effects**:
- QTc prolongation (greatest with moxifloxacin)
- Photosensitivity
- GI upset
- Dysglycemia (hypo- or hyperglycemia)
- C. difficile infection

**Drug Interactions**:
- **Divalent/trivalent cations**: Separate from antacids, calcium, iron, zinc by 2-6 hours
- **QTc-prolonging drugs**: Avoid concurrent use
- **Tizanidine**: Contraindicated with ciprofloxacin

**Clinical Pearls**:
- FDA recommends reserving for serious infections when alternatives unavailable
- Excellent oral bioavailability allows IV-to-PO conversion
- Avoid in pregnancy/children (cartilage damage in animal studies)

---

## Aminoglycosides (Pages 7-9)

### General Characteristics

**Mechanism of Action**:
- Bind to 30S ribosomal subunit → inhibit protein synthesis
- Concentration-dependent bactericidal activity
- **PK/PD target**: Cmax/MIC ratio of 8-10

**Spectrum of Activity**:
- Gram-negative organisms (including Pseudomonas)
- Synergy with beta-lactams for Gram-positives (e.g., Enterococcus)
- **No activity**: Anaerobes (require oxygen for uptake)

### Individual Agents

**Gentamicin**:
- **Indications**: Gram-negative sepsis, synergy for Enterococcus endocarditis, pyelonephritis
- **Dosing**:
  - Traditional: 1-2.5 mg/kg q8h
  - Extended-interval: 5-7 mg/kg q24h (preferred)

**Tobramycin**:
- **Similar to gentamicin** but slightly better Pseudomonas coverage
- **Inhaled formulation**: For CF patients with Pseudomonas

**Amikacin**:
- **Advantage**: Resistant to many aminoglycoside-modifying enzymes
- **Reserve for resistant organisms**
- **Dosing**: 15-20 mg/kg q24h

### Pharmacokinetics

- **Distribution**: Hydrophilic; poor penetration into CNS, abscesses, respiratory secretions
- **Elimination**: 100% renal excretion; adjust dose for renal impairment
- **Half-life**: 2-3 hours (normal renal function)

### Dosing Strategies

**Extended-Interval Dosing (Preferred)**:
- **Gentamicin/Tobramycin**: 5-7 mg/kg q24h
- **Amikacin**: 15-20 mg/kg q24h
- **Advantages**:
  - Enhanced efficacy (concentration-dependent killing)
  - Reduced toxicity (longer drug-free periods)
  - Convenient dosing
- **Monitoring**: Random level 6-14 hours post-dose

**Traditional Dosing**:
- Reserved for specific situations (endocarditis, pregnancy, severe burns)
- **Monitoring**: Peak and trough levels

### Adverse Effects

**Nephrotoxicity** (10-25% of patients):
- **Risk factors**: Prolonged therapy (>3-5 days), high trough levels, concurrent nephrotoxins, volume depletion
- **Monitoring**: SCr, BUN every 2-3 days
- **Usually reversible** if caught early

**Ototoxicity** (Vestibular and Cochlear):
- **Vestibular**: Vertigo, ataxia, nystagmus
- **Cochlear**: Tinnitus, hearing loss (often permanent)
- **Risk factors**: Prolonged therapy, high peak levels, concurrent ototoxins
- **Monitoring**: Audiometry at baseline and during therapy

**Neuromuscular Blockade**:
- Rare; risk with rapid IV infusion
- Enhanced with neuromuscular blocking agents

### Clinical Pearls

- **Always use in combination** (never monotherapy) - rapid resistance development
- Extended-interval dosing preferred for most indications
- Not effective for pneumonia (poor lung penetration)
- Synergy with beta-lactams critical for serious Gram-positive infections
- Avoid concurrent nephrotoxins (vancomycin, NSAIDs, contrast)

---

## Macrolides (Pages 9-10)

### General Characteristics

**Mechanism of Action**:
- Bind to 50S ribosomal subunit → inhibit protein synthesis
- **Bacteriostatic** (bactericidal at high concentrations)

**Spectrum of Activity**:
- Gram-positive organisms (Streptococcus, some Staph)
- Atypical organisms (Mycoplasma, Chlamydia, Legionella)
- Some Gram-negatives (H. influenzae - azithromycin)

### Individual Agents

**Erythromycin**:
- **First-generation macrolide**
- **Dosing**: 250-500 mg PO q6h OR 500 mg-1 g IV q6h
- **Disadvantages**:
  - Poor GI tolerance (high rates of nausea, cramping, diarrhea)
  - Multiple daily doses
  - Significant drug interactions (CYP3A4 inhibitor)
- **Clinical use**: Limited due to tolerability; mostly replaced by newer agents

**Clarithromycin (Biaxin)**:
- **Advantages**:
  - Better GI tolerance than erythromycin
  - Twice-daily dosing
  - Better tissue penetration
- **Dosing**: 250-500 mg PO q12h OR 1000 mg XL q24h
- **Indications**: CAP, H. pylori eradication, MAC prophylaxis
- **Drug interactions**: Strong CYP3A4 inhibitor

**Azithromycin (Zithromax, Z-Pak)**:
- **Advantages**:
  - Excellent tissue penetration and concentration
  - Long half-life (68 hours) allows once-daily dosing
  - Short treatment courses (3-5 days)
  - Fewer drug interactions (minimal CYP inhibition)
- **Dosing**:
  - 500 mg PO × 1, then 250 mg q24h × 4 days (Z-Pak)
  - OR 500 mg PO q24h × 3 days
  - OR 1-2 g PO × 1 dose (for certain STIs)
- **Indications**: CAP, atypical pneumonia, STIs (chlamydia, gonorrhea), traveler's diarrhea
- **Spectrum**: Better Gram-negative coverage than other macrolides

### Adverse Effects

**Gastrointestinal**:
- Nausea, vomiting, diarrhea, abdominal pain
- **Mechanism**: Motilin receptor agonist → prokinetic effects
- **Highest with erythromycin**, lowest with azithromycin

**Cardiovascular**:
- **QTc prolongation**: All macrolides (greatest with azithromycin)
- **Risk factors**: Pre-existing cardiac disease, concurrent QTc-prolonging drugs
- **FDA warning**: Increased cardiovascular death risk with azithromycin

**Hepatotoxicity**:
- Rare cholestatic hepatitis (especially with erythromycin estolate)

### Drug Interactions

**CYP3A4 Inhibition** (erythromycin > clarithromycin >> azithromycin):
- **Increased levels of**: Statins, warfarin, digoxin, theophylline, carbamazepine, tacrolimus
- **Clinical significance**: May require dose adjustments or monitoring

### Resistance

- **Mechanism**: Methylation of 23S rRNA (erm genes)
- **Cross-resistance**: Among all macrolides
- **Increasing resistance**: Particularly in Streptococcus pneumoniae (20-40% in some areas)

### Clinical Pearls

- Excellent for atypical pneumonia coverage
- Azithromycin preferred for most indications (tolerability, convenience)
- Monitor QTc in high-risk patients
- Avoid in patients with history of cholestatic jaundice
- Azithromycin concentrates in WBCs → delivered to infection sites

---

## Tetracyclines (Pages 11-12)

### General Characteristics

**Mechanism of Action**:
- Bind to 30S ribosomal subunit → inhibit protein synthesis
- **Bacteriostatic**

**Spectrum of Activity**:
- Broad spectrum: Gram-positives, Gram-negatives, atypicals, rickettsiae, spirochetes
- Notable coverage: MRSA, anaerobes (tigecycline), multidrug-resistant organisms

### Individual Agents

**Doxycycline (Vibramycin)**:
- **Most commonly used tetracycline**
- **Dosing**: 100 mg PO/IV q12h
- **Oral bioavailability**: 90-100%
- **Indications**:
  - CAP (with beta-lactam)
  - Tick-borne diseases (Lyme, RMSF, ehrlichiosis)
  - ABSSSI (including MRSA)
  - Acne
  - Malaria prophylaxis
- **Advantages**: Twice-daily dosing, less GI upset than tetracycline, can be taken with food

**Minocycline (Minocin)**:
- **Similar to doxycycline**
- **Dosing**: 100 mg PO q12h OR 200 mg × 1, then 100 mg q12h
- **Indications**: Acne, MRSA ABSSSI
- **Unique adverse effect**: Vestibular toxicity (dizziness, vertigo)

**Tigecycline (Tygacil)**:
- **Glycylcycline** (tetracycline derivative)
- **Broad spectrum**: MRSA, VRE, ESBL-producing organisms, anaerobes
- **No activity**: Pseudomonas, Proteus
- **Dosing**: 100 mg IV × 1, then 50 mg IV q12h
- **Indications**: Complicated intra-abdominal infections, ABSSSI, CAP
- **Black Box Warning**: Increased mortality vs. comparators - reserve for limited treatment options
- **Adverse effects**: Nausea/vomiting (very common), pancreatitis

**Eravacycline (Xerava)**:
- **Fluorocycline** (tetracycline derivative)
- **Indication**: Complicated intra-abdominal infections
- **Dosing**: 1 mg/kg IV q12h
- **Advantages**: Less nausea than tigecycline, active against some tigecycline-resistant organisms

**Omadacycline (Nuzyra)**:
- **Aminomethylcycline** (tetracycline derivative)
- **Indications**: CAP, ABSSSI
- **Dosing**:
  - IV: 100 mg q12h × 2 doses, then 100 mg q24h
  - PO: 300 mg q24h
- **Advantage**: Oral and IV formulations

### Adverse Effects

**Gastrointestinal**:
- Nausea, vomiting, diarrhea (common)
- Esophagitis/esophageal ulceration (take with full glass of water, remain upright)

**Photosensitivity**:
- Severe sunburn with minimal sun exposure
- **Prevention**: Use sunscreen, avoid excessive sun exposure

**Tooth Discoloration**:
- Permanent staining in children <8 years
- **Contraindicated**: Pregnancy, breastfeeding, children <8 years

**Hepatotoxicity**:
- Rare; dose-related
- Risk with IV administration and high doses

**Drug Interactions**:
- **Chelation**: Divalent/trivalent cations (calcium, iron, magnesium, aluminum)
  - Separate by 2-3 hours
- **Reduced efficacy**: Antacids, dairy products, iron supplements

### Clinical Pearls

- Doxycycline is drug of choice for tick-borne illnesses
- Tigecycline reserved for multidrug-resistant organisms with limited options
- Excellent tissue penetration
- Avoid in pregnancy and young children
- Take on empty stomach when possible (except doxycycline/minocycline - can take with food)

---

## Other Key Antibacterials (Pages 13-15)

### Clindamycin (Cleocin)

**Mechanism of Action**:
- Inhibits bacterial protein synthesis (50S ribosomal subunit)
- **Bacteriostatic**

**Spectrum of Activity**:
- Gram-positive cocci (including MRSA)
- Anaerobes (especially Bacteroides fragilis)
- **No activity**: Gram-negatives, Enterococcus

**Indications**:
- ABSSSI (including MRSA)
- Aspiration pneumonia
- Intra-abdominal infections (with Gram-negative coverage)
- Toxin suppression (toxic shock syndrome, necrotizing fasciitis)
- Alternative for beta-lactam allergic patients

**Dosing**:
- **PO**: 150-450 mg q6-8h
- **IV**: 600-900 mg q8h

**Adverse Effects**:
- **C. difficile infection**: High risk (10-30%)
- GI upset
- Rash

**Clinical Pearls**:
- Excellent bone penetration (use for osteomyelitis)
- Suppresses toxin production in S. aureus and Streptococcus
- Good anaerobic coverage for dental/oral infections
- Alternative to beta-lactams for MSSA

### Trimethoprim/Sulfamethoxazole (Bactrim, Septra)

**Mechanism of Action**:
- **Sequential blockade** of folic acid synthesis
  - Sulfamethoxazole: Inhibits dihydropteroate synthase
  - Trimethoprim: Inhibits dihydrofolate reductase
- **Bactericidal** in combination

**Spectrum of Activity**:
- Broad spectrum: MRSA, MSSA, Gram-negatives (E. coli, Klebsiella)
- Special coverage: Pneumocystis jirovecii, Stenotrophomonas maltophilia, Nocardia

**Indications**:
- UTI (first-line)
- MRSA ABSSSI
- Pneumocystis pneumonia (PCP) treatment and prophylaxis
- Toxoplasmosis
- Stenotrophomonas infections

**Dosing**:
- **Standard**: 1 DS (double-strength) tablet PO q12h
- **High-dose** (PCP treatment): 5 mg/kg (TMP component) IV q6-8h
- **PCP prophylaxis**: 1 DS tablet PO daily or 3×/week

**Adverse Effects**:
- **Hyperkalemia**: Trimethoprim acts as potassium-sparing diuretic
- **Nephrotoxicity**: SCr elevation (not true kidney damage - blocks tubular secretion)
- **Rash**: Common (3-5%); Stevens-Johnson syndrome in severe cases
- **GI upset**: Nausea, vomiting
- **Bone marrow suppression**: Especially with prolonged use
- **Drug interactions**: Warfarin (increases INR), methotrexate, phenytoin

**Contraindications**:
- Sulfa allergy
- Pregnancy (especially 1st and 3rd trimesters)
- Severe renal impairment (CrCl <15 mL/min)

**Clinical Pearls**:
- Excellent oral bioavailability (~100%)
- First-line for uncomplicated UTI in many areas
- Monitor potassium and SCr during therapy
- May cause falsely elevated SCr (interference with assay)

### Metronidazole (Flagyl)

**Mechanism of Action**:
- Disrupts DNA and inhibits nucleic acid synthesis (requires reduction in anaerobic environment)
- **Bactericidal** against anaerobes

**Spectrum of Activity**:
- **Excellent anaerobic coverage**: Bacteroides, Clostridium (including C. difficile), Prevotella
- Protozoa: Giardia, Entamoeba, Trichomonas
- **No activity**: Aerobic bacteria

**Indications**:
- C. difficile infection (oral)
- Intra-abdominal infections (with Gram-negative/positive coverage)
- Bacterial vaginosis
- Trichomoniasis
- Giardiasis
- Aspiration pneumonia (with other agents)
- H. pylori eradication

**Dosing**:
- **C. diff**: 500 mg PO q8h × 10 days
- **Intra-abdominal**: 500 mg IV q8h
- **Trichomoniasis**: 2 g PO × 1 OR 500 mg PO q12h × 7 days

**Adverse Effects**:
- **Disulfiram-like reaction**: Severe nausea, vomiting, flushing with alcohol
  - Avoid alcohol during therapy and for 3 days after
- **Metallic taste**: Very common
- **Peripheral neuropathy**: Prolonged use (>2 weeks)
- **GI upset**: Nausea, anorexia

**Drug Interactions**:
- **Warfarin**: Increases INR
- **Alcohol**: Disulfiram-like reaction
- **Lithium**: Increased lithium levels

**Clinical Pearls**:
- Oral and IV formulations have similar bioavailability
- Excellent CNS penetration (use for brain abscesses)
- Avoid in first trimester of pregnancy
- Warn patients about alcohol interaction

### Rifampin (Rifadin)

**Mechanism of Action**:
- Inhibits bacterial RNA polymerase
- **Bactericidal**

**Spectrum of Activity**:
- Mycobacteria (TB, MAC)
- Staphylococcus (including MRSA)
- Gram-positives

**Indications**:
- **Combination therapy only** (never monotherapy - rapid resistance)
- Tuberculosis (as part of multi-drug regimen)
- Staphylococcal prosthetic joint infections (with other agents)
- MRSA bacteremia/endocarditis (adjunctive)
- Bacterial meningitis prophylaxis (N. meningitidis, H. influenzae)

**Dosing**:
- **TB treatment**: 10 mg/kg (max 600 mg) PO q24h
- **Staph infections**: 300-450 mg PO q12h
- **Meningitis prophylaxis**: 600 mg PO q12h × 2 days

**Adverse Effects**:
- **Orange discoloration**: Urine, tears, sweat, saliva (warn patients; may stain contact lenses)
- **Hepatotoxicity**: Monitor LFTs
- **Drug interactions**: Potent CYP3A4 inducer
  - Decreases levels of: Oral contraceptives, warfarin, protease inhibitors, many others
  - Requires alternative contraception

**Clinical Pearls**:
- ALWAYS use in combination (resistance develops within days if used alone)
- Patients must be counseled on orange body fluid discoloration
- Excellent biofilm penetration (valuable for device-related infections)
- Strong CYP3A4 inducer - check for drug interactions

### Nitrofurantoin (Macrobid, Macrodantin)

**Mechanism of Action**:
- Damages bacterial DNA through reactive intermediates
- **Bactericidal** at urinary concentrations

**Spectrum of Activity**:
- E. coli, Enterococcus, Staphylococcus saprophyticus
- **No activity**: Pseudomonas, Proteus, Serratia, Klebsiella (many strains)

**Indications**:
- **Uncomplicated UTI only** (cystitis)
- UTI prophylaxis
- **NOT for pyelonephritis** (inadequate tissue levels)

**Dosing**:
- **Macrobid (monohydrate/macrocrystals)**: 100 mg PO q12h × 5-7 days
- **Prophylaxis**: 50-100 mg PO qHS

**Adverse Effects**:
- **Pulmonary toxicity**: Acute (pneumonitis) or chronic (pulmonary fibrosis)
  - Risk increases with prolonged use (>6 months)
- **Peripheral neuropathy**: Especially with renal impairment
- **GI upset**: Nausea (reduced by taking with food)
- **Hemolytic anemia**: In G6PD deficiency

**Contraindications**:
- CrCl <30 mL/min (inadequate urinary concentrations)
- Pregnancy at term (risk of hemolytic anemia in newborn)
- G6PD deficiency

**Clinical Pearls**:
- Macrocrystalline formulation (Macrobid) better tolerated than microcrystalline
- Take with food to reduce GI upset
- Only achieves therapeutic levels in urine - not for systemic infections
- Resistance rates lower than TMP/SMX for E. coli UTI
- Monitor for pulmonary symptoms during long-term prophylaxis

---

## Summary Tables

### Drugs for Resistant Gram-Positive Organisms

| Drug | Spectrum | Key Indication | Major Toxicity | Monitoring |
|------|----------|----------------|----------------|------------|
| Vancomycin | MRSA, Strep, Enterococcus | Serious MRSA infections | Nephrotoxicity, ototoxicity | Trough levels, SCr |
| Daptomycin | MRSA, VRE | Bacteremia, endocarditis | CPK elevation, myopathy | CPK weekly |
| Linezolid | MRSA, VRE | VRE infections | Myelosuppression, neuropathy | CBC weekly if >2 weeks |
| Tedizolid | MRSA | ABSSSI | Lower toxicity than linezolid | Minimal |

### Fluoroquinolone Comparison

| Drug | Gram-Positive | Gram-Negative | Pseudomonas | Anaerobes | Atypicals |
|------|---------------|---------------|-------------|-----------|-----------|
| Ciprofloxacin | + | ++++ | ++++ | - | +++ |
| Levofloxacin | +++ | +++ | ++ | - | ++++ |
| Moxifloxacin | ++++ | ++ | - | +++ | ++++ |
| Delafloxacin | ++++ (MRSA) | +++ | + | ++ | +++ |

### Aminoglycoside Dosing

| Drug | Standard Dose | Extended-Interval Dose | Peak Goal | Trough Goal |
|------|---------------|------------------------|-----------|-------------|
| Gentamicin | 1-2.5 mg/kg q8h | 5-7 mg/kg q24h | 5-10 mcg/mL | <2 mcg/mL |
| Tobramycin | 1-2.5 mg/kg q8h | 5-7 mg/kg q24h | 5-10 mcg/mL | <2 mcg/mL |
| Amikacin | 5-7.5 mg/kg q8h | 15-20 mg/kg q24h | 20-30 mcg/mL | <10 mcg/mL |

---

**End of Module 15**
